Highlights from

European Respiratory Society

Congress 2018

Paris 15-19 September 2018

Brain metastases, lung cancer and interstitial lung disease

According to Dr Torsten Blum (Helios Klinikum, Berlin-Zehlendorf, Germany), brain metastases can be present already at diagnosis of lung cancer. A population-based study from the USA showed that patients with lung cancer had the highest proportion of brain metastases at time of primary cancer diagnosis (10.8%) among the evaluated cancer types [12]. Of the brain metastases, approximately 10-20% are synchronous [13] and 40-50% metachronous [14]. Brain metastases are most frequently located in the cerebrum (80%), followed by the cerebellum (15%) and brain stem (5%) [15].

“With respect to the pathogenesis of brain metastases, we should be aware of the blood-brain barrier [16]. In its function as security control, blocking potentially toxic substances from entering the brain, it puts a limitation on which drugs can be used.” The formation of brain metastases is based on the ‘seed and soil’ concept, so an interaction between the brain tissue and tumour cells. Multiple pathways are involved in this process. The ALK, EGFR, and VEGF pathways stimulate the proliferation, cell invasion, and angiogenesis of tumour cells, respectively [17].

Multimodal management of brain metastases

The possibility of surgical resection of brain metastases was studied in the early nineties of the previous century. “Some publications showed that surgical resection in addition to whole brain radiotherapy could improve survival”, stated Dr Blum. “Later on, it was shown that surgical resection alone led to a higher recurrence rate.” In 2016, the results of the QUARTZ trial, evaluating dexamethasone plus best supportive care with or without whole brain radiotherapy, showed a similar median overall survival between both groups (overall survival 9.2 vs 8.5 weeks, respectively; HR 1.06; P=0.8084). The same was true for the quality of life outcomes [18]. “But, a frequently suggested point of critique about this trial is that it included very sick patients with advanced disease who were unsuitable for stereotactic radiotherapy.”

Finally, Dr Blum mentioned the developments in the field of systemic treatment of brain metastases. “What is really thrilling nowadays, are the targeted therapies. We currently have some data with respect to the effect on brain metastases, although in small patient groups. EGFR-targeted treatments showed quite high response rates [19] and an improved PFS and overall survival [20]. “We are all awaiting the data of osimertinib in the treatment of brain metastases. And for ALK-targeted treatments, we have comparable promising figures” [21].

Lung cancer and interstitial lung disease

Prof. Jacques Cadranel (Constitutive Center on Rare Pulmonary Diseases, Paris, France) stated that there is an association between different forms of interstitial lung disease (ILD) [22], especially interstitial lung fibrosis (IPF), and the risk of lung cancer. Both conditions have common risk factors, such as higher age and smoking [23]. Lung cancer in IPF patients mainly presents in the lower lobe, usually in a lobe with fibrosis. The volume double time of a lung cancer nodule is usually ≤90 days [24]. The treatment of locally advanced NSCLC should be a combination of radiation therapy and chemotherapy. However, there are very few studies evaluating the efficacy and toxicity of conventional radiation therapy in patients with ILD-associated lung cancer. In total, 27-31% of radiation pneumonitis in IPF and 54% of fatal radiation pneumonitis were from patients with pre-treatment ILD [25]. According to Prof. Cadranel, conventional radiation therapy should not be used in lung cancer patients with IPF [26].

  1. Kromer C, et al. J Neurooncol. 2017;134:55-64.
  2. Waqar SN, et al. Clin Lung Cancer. 2018;19:e373-e379.
  3. Yawn BP, et al. Minn Med. 2003;86:32-7.
  4. Takei H, et al. Brain Tumor Pathol. 2016;33:1-12.
  5. Ciminera AK, et al. Clin Exp Metastasis. 2017;34:401-410.
  6. Ni W, et al. Cancer Med. 2018;7:3820-3833.
  7. Mulvenna P, et al. Lancet. 2016;388:2004-2014.
  8. Ulahannan D, et al. Ann Oncol. 2017;28:2923-2931.
  9. Wang X, et al. Transl Oncol. 2018;11:1119-1127.
  10. Waqar SN, et al. Hematol Oncol Clin North Am. 2017;31:157-176.
  11. Travis WD, et al. Am J Respir Crit Care Med. 2013;188:733-48.
  12. Meiners S, et al. Eur Respir J. 2015;45:807-27.
  13. Tzouvelekis A, et al. Lancet Respir Med. 2018;6:86-88.
  14. Vogelius IR, Bentzen SM. Acta Oncol. 2012;51:975-83.
  15. Vansteenkiste J, et al. Ann Oncol. 2013;24 Suppl 6:vi89-98.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.